BackIonis Pharmaceuticals Overview
Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Target Price

Where could IONS trade next? Consensus target price: $87.

Get informed when a big investor buys or sells

+ Follow

Share Price

$45.75

Average Target Price

$86.5089.1% upside

20 analysts in the last 4 months

High: $130 | Low: $54

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-15GuggenheimDebjit Chattopadhyay$8074.9% upsideOpen
2026-09-09Barclays$8585.8% upsideOpen
2026-09-08Raymond JamesTiago Fauth$8483.6% upsideOpen
2026-09-08Morgan StanleyMichael Ulz$104127.3% upsideOpen
2026-09-08Canaccord Genuity$8585.8% upsideOpen
2026-09-08BMO Capital$5418% upsideOpen
2026-09-08Goldman Sachs$5622.4% upsideOpen
2026-09-04BMO CapitalDavid Lebowitz$6133.3% upsideOpen
2026-07-30H.C. WainwrightMitchell Kapoor$115151.4% upsideOpen
2026-07-29Goldman Sachs$6950.8% upsideOpen
2026-07-21GuggenheimDebjit Chattopadhyay$8994.5% upsideOpen
2026-07-13RBC CapitalLuca Issi$8585.8% upsideOpen
2026-07-10Morgan Stanley$110140.4% upsideOpen
2026-07-10Canaccord GenuityGary Nachman$95107.7% upsideOpen
2026-07-10BarclaysEliana Merle$9096.7% upsideOpen
2026-07-09Jefferies$9096.7% upsideOpen
2026-07-09NeedhamJoseph Stringer$8688% upsideOpen
2026-07-09Raymond James$8790.2% upsideOpen
2026-06-25H.C. Wainwright$130184.2% upsideOpen
2026-06-24Goldman Sachs$7563.9% upsideOpen
2026-04-30Oppenheimer$111142.6% upsideOpen
2026-04-30H.C. Wainwright$125173.2% upsideOpen
2026-04-30BarclaysEliana Merle$115151.4% upsideOpen
2026-04-21Morgan Stanley$130184.2% upsideOpen
2026-04-20Canaccord Genuity$110140.4% upsideOpen
2026-04-10Raymond JamesTiago Fauth$104127.3% upsideOpen
2026-02-25Morgan StanleyMichael Ulz$95107.7% upsideOpen
2026-02-25Needham$103125.1% upsideOpen
2026-02-06Piper Sandler$8790.2% upsideOpen
2026-01-05Wells Fargo$100118.6% upsideOpen
2025-12-17RBC CapitalLuca Issi$95107.7% upsideOpen
2025-12-15Leerink Partners$100118.6% upsideOpen
2025-11-04Piper Sandler$7768.3% upsideOpen
2025-10-30H.C. Wainwright$100118.6% upsideOpen
2025-10-30Morgan Stanley$94105.5% upsideOpen
2025-10-30Cowen & Co.$99116.4% upsideOpen
2025-10-30Barclays$95107.7% upsideOpen
2025-10-16Morgan Stanley$9096.7% upsideOpen
2025-10-08OppenheimerJustin Kim$9096.7% upsideOpen
2025-10-06Stifel Nicolaus$6746.4% upsideOpen
2025-09-26Goldman Sachs$6542.1% upsideOpen
2025-09-23BarclaysGena Wang$8279.2% upsideOpen
2025-09-22Raymond JamesGary Nachman$7563.9% upsideOpen
2025-09-04RBC Capital$8074.9% upsideOpen
2025-09-03BMO CapitalKostas Biliouris$7053% upsideOpen
2025-09-02BarclaysGena Wang$7870.5% upsideOpen
2025-09-02Morgan StanleyMichael Ulz$7155.2% upsideOpen
2025-09-02Jefferies$96109.8% upsideOpen
2025-09-02H.C. WainwrightMitchell Kapoor$95107.7% upsideOpen
2025-08-22H.C. Wainwright$7053% upsideOpen

Ionis Pharmaceuticals (IONS) FAQ

Ionis Pharmaceuticals posts a target price of $87. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $87 for IONS means covering analysts, on average, see the stock 89.1% upside of $45.75 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for IONS's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Ionis Pharmaceuticals's other metric pages and overview cover the third.

Judging Ionis Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $87 here, then scan peer and history charts to see if the gap is persistent.